We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 5.00 | 0.29% | 1,733.50 | 1,732.50 | 1,733.00 | 1,739.50 | 1,724.50 | 1,733.00 | 4,237,056 | 16:35:18 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 14.48 | 71.35B |
From May 2021 to May 2024
By Cecilia Butini
GlaxoSmithKline PLC said Friday that five Phase 3 studies of a drug used to treat patients with anemia due to chronic kidney disease have met their primary efficacy endpoint.
The British pharmaceutical major said the studies evaluated the efficacy and safety of the drug, named daprodustat, as part of a Phase 3 program named Ascend. As a primary endpoint, the drug demonstrated an improvement in hemoglobin levels both in patients who weren't receiving other treatments and in patients treated with another standard treatment option, the company said.
GSK said daprodustat is currently only approved in Japan for patients with renal anemia and that it isn't approved in any other country.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
July 16, 2021 07:49 ET (11:49 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
